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Vitamin D metabolism in thyrotoxicosis. Therapeutic aspects derived
from an old observation
To the Editor:
In an article of 2007 about vitamin D deﬁ-
ciency, it was reported that low 25OH-vitD
(25hydroxyvitaminD) plasma levels are found
in thyrotoxicosis, with thyrotoxicosis being
the last in the list of acquired causes of vita-
min D deﬁciency (1). We ﬁrst demonstrated
low 25OH-vitD plasma levels in thyrotoxico-
sis (2), as well as the fact that the transforma-
tion of vitamin D into 25OH-vitD is 2.5 to
eight times faster in thyrotoxic subjects in
comparison to healthy controls (3).
In an unpublished report, the acceleration of
hydroxylation of vitamin D into 25OH-vitD in
thyrotoxic subjects (TS) was depicted against
that of healthy controls (HC) (Figure 1).
When our observations were made, the
lower normal limits of 25OH-vitD plasma lev-
els were ill deﬁned as various cut points were
used for a long time to deﬁne vitamin D inad-
equacy ﬂuctuating from 9 ng⁄ml to 30 ng⁄ml
(4). Therefore, it was inconvenient to consider
hypovitaminosis D with 25OH-vitD plasma
levels between 9 ng⁄ml and 30 ng⁄ml.
These nebulous data about the lower nor-
mal limits of 25OH-vitD plasma levels
resulted in the lack of concern regarding the
acceleration of vitamin D metabolism in thy-
rotoxicosis, although the osteomalacic com-
ponent has been mentioned long ago in
thyrotoxic bone disease (5).
In recent years, a level of 30 ng⁄ml or
greater of 25OH-vitD plasma levels was
approved deﬁnitely as the lower normal level
in humans, while the toxic levels were deﬁned
as greater than 150 ng⁄ml (1). The new data
validated the ascertained acceleration of vita-
min metabolism in thyrotoxicosis as thyrotoxic
subjects are at risk for drop of 25OH-vitD
plasma levels below the level of 30 ng⁄ml. In
addition, hyperthyroidism is an endocrinopa-
thy, which may run for a long time without the
patient seeking medical intervention. Hence,
the vitamin D depot in the body may decline
in the levels of inadequacy or overt deﬁciency
with the all known consequences. Especially
prone to this risk are the thyrotoxic subjects of
old age or institutionalised as well as those
conﬁned at home. A similar condition may be
observed in patients taking suppressive doses
of thyroxine or incorrectly increased doses of
replacement therapy.
The aim of this issue is to establish in all
patients who are under the inﬂuence of
increased thyroid hormones, a testing of their
vitamin D status parallel to the testing of
their thyroid status, as well as the follow-up
of their 25OH-vitD plasma levels during the
medical supervision of the patient.
The intervention with vitamin D when
insufﬁciency or deﬁciency of this vitamin
ensues will avert the deleterious effect of this
inadequacy especially to the bones.
This substance ‘vitamin D-hormone’, on
the basis of the above mentioned, must be
considered as a serious agent in the restora-
tion of health after the elapse of toxicosis in
thyrotoxic patients, given the fact that many
are unaware of this kind of inadequacy in
thyrotoxic subjects.
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Figure 1 25hydroxyvitaminD plasma levels estimated the same period in three thyrotoxic subjects (TS) and
three healthy controls (HC), all males matched for age and body weight after i.v. injection of 1 mg of
vitamin D
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